Your browser doesn't support javascript.
loading
Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan, A M; Hughes, A T; Davison, A S; Khedr, M; Rovensky, J; Psarelli, E E; Cox, T F; Rhodes, N P; Gallagher, J A; Ranganath, L R.
Afiliação
  • Milan AM; Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK. anna.milan@rlbuht.nhs.uk.
  • Hughes AT; Department of Musculoskeletal Biology, University of Liverpool, L7 8TX, Liverpool, UK. anna.milan@rlbuht.nhs.uk.
  • Davison AS; Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK.
  • Khedr M; Department of Musculoskeletal Biology, University of Liverpool, L7 8TX, Liverpool, UK.
  • Rovensky J; Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK.
  • Psarelli EE; Department of Musculoskeletal Biology, University of Liverpool, L7 8TX, Liverpool, UK.
  • Cox TF; Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK.
  • Rhodes NP; National Institute of Rheumatic Diseases, Piestany, Slovakia.
  • Gallagher JA; Liverpool Cancer Trials Unit, University of Liverpool, Block C, Waterhouse Building, Liverpool, L69 3GL, UK.
  • Ranganath LR; Liverpool Cancer Trials Unit, University of Liverpool, Block C, Waterhouse Building, Liverpool, L69 3GL, UK.
Sci Rep ; 9(1): 10024, 2019 07 11.
Article em En | MEDLINE | ID: mdl-31296884
ABSTRACT
Nitisinone decreases homogentisic acid (HGA) in Alkaptonuria (AKU) by inhibiting the tyrosine metabolic pathway in humans. The effect of different daily doses of nitisinone on circulating and 24 h urinary excretion of phenylalanine (PA), tyrosine (TYR), hydroxyphenylpyruvate (HPPA), hydroxyphenyllactate (HPLA) and HGA in patients with AKU was studied over a four week period. Forty AKU patients, randomised into five groups of eight patients, received doses of 1, 2, 4 or 8 mg of nitisinone daily, or no drug (control). Metabolites were analysed by tandem mass spectrometry in 24 h urine and serum samples collected before and after nitisinone. Serum metabolites were corrected for total body water and the sum of 24 hr urine plus total body water metabolites of PA, TYR, HPPA, HPLA and HGA were determined. Body weight and urine urea were used to check on stability of diet and metabolism over the 4 weeks of study. The sum of quantities of urine metabolites (PA, TYR, HPPA, HPLA and HGA) were similar pre- and post-nitisinone. The sum of total body water metabolites were significantly higher post-nitisinone (p < 0.0001) at all doses. Similarly, combined 24 hr urinetotal body water ratios for all analytes were significantly higher post-nitisinone, compared with pre-nitisinone baseline for all doses (p = 0.0002 - p < 0.0001). Significantly higher concentrations of metabolites from the tyrosine metabolic pathway were observed in a dose dependant manner following treatment with nitisinone and we speculate that, for the first time, experimental evidence of the metabolite pool that would otherwise be directed towards pigment formation, has been unmasked.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tirosina / Cicloexanonas / Alcaptonúria / Nitrobenzoatos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tirosina / Cicloexanonas / Alcaptonúria / Nitrobenzoatos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article